Answer Summary Cold calling payers is a low-yield game because relationship-based applications yield a 25% higher success rate than cold submissions, which frequently stall at a dismal 22% closure rate. Transitioning to a Relationship Management Program is a vital strategic…
Answer Summary: With High-Deductible Health Plans (HDHPs) dominating the commercial market in 2026, the “Patient Responsibility” portion of a DME bill has grown from 20% to often 50% or more. Collecting this money after the equipment is delivered has a…
Answer Summary: Urological supplies (catheters, bags) represent a stable, high-margin, recurring revenue stream that is less volatile than competitive bid items like Oxygen. However, credentialing for urologicals requires specific attention to State Pharmacy Board regulations, as many states classify sterile…
Answer Summary: Negotiating contracts with major commercial payers (UnitedHealthcare, Aetna, Cigna) requires a different strategy than Medicare enrollment. These payers are not obligated to let you in. To succeed in 2026, DME providers must move beyond “filling out the form”…
Answer Summary The 2026 Competitive Bidding Window is officially closed. Now begins the “Great Silence”—a period of 4–5 months where providers wait for Preliminary Bid Evaluations. The most dangerous mistake a DME provider can make in August is to pause…
